AERIE PHARMACEUTICALS INC's ticker is AERI and the CUSIP is 00771V108. A total of 152 filers reported holding AERIE PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.08 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $6,136,000 | +9.0% | 454,216 | -5.0% | 0.03% | 0.0% |
| Q3 2020 | $5,630,000 | -36.7% | 478,366 | -20.7% | 0.03% | -43.1% |
| Q2 2020 | $8,898,000 | -41.7% | 602,866 | -46.7% | 0.05% | -48.5% |
| Q1 2020 | $15,265,000 | +0.6% | 1,130,795 | +80.0% | 0.10% | +30.3% |
| Q4 2019 | $15,181,000 | +37.5% | 628,095 | +9.3% | 0.08% | +24.6% |
| Q3 2019 | $11,042,000 | – | 574,545 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management II, LLC | 805,217 | $14,212,000 | 4.99% |
| DAFNA Capital Management LLC | 156,842 | $2,768,000 | 2.34% |
| NORTHPOINTE CAPITAL LLC | 1,034,400 | $18,257,000 | 2.15% |
| HARVEY CAPITAL MANAGEMENT INC | 223,200 | $3,856,000 | 1.30% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,211,644 | $39,036,000 | 1.30% |
| Boulegeris Investments, Inc. | 88,660 | $1,565,000 | 1.12% |
| Partner Investment Management, L.P. | 43,623 | $770,000 | 1.08% |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 150,000 | $2,648,000 | 0.92% |
| PFM Health Sciences, LP | 1,851,564 | $32,680,000 | 0.83% |
| Benchmark Capital Advisors | 55,400 | $978,000 | 0.69% |